key: cord-0910350-i4rlu0r0
authors: Ali, Farak; Alom, Shahnaz; Shakya, Anshul; Ghosh, Surajit K.; Singh, Udaya P.; Bhat, Hans R.
title: Implication of in silico studies in the search for novel inhibitors against SARS‐CoV‐2
date: 2022-03-04
journal: Arch Pharm (Weinheim)
DOI: 10.1002/ardp.202100360
sha: 6ec7d46bdf9727c8ccb479d46eea1c40fa1677ac
doc_id: 910350
cord_uid: i4rlu0r0

Corona Virus Disease‐19 (COVID‐19) is a pandemic disease mainly caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). It had spread from Wuhan, China, in late 2019 and spread over 222 countries and territories all over the world. Earlier, at the very beginning of COVID‐19 infection, there were no approved medicines or vaccines for combating this disease, which adversely affected a lot of individuals worldwide. Although frequent mutation leads to the generation of more deadly variants of SARS‐CoV‐2, researchers have developed several highly effective vaccines that were approved for emergency use by the World Health Organization (WHO), such as mRNA‐1273 by Moderna, BNT162b2 by Pfizer/BioNTech, Ad26.COV2.S by Janssen, AZD1222 by Oxford/AstraZeneca, Covishield by the Serum Institute of India, BBIBP‐CorV by Sinopharm, coronaVac by Sinovac, and Covaxin by Bharat Biotech, and the first US Food and Drug Administration‐approved antiviral drug Veklury (remdesivir) for the treatment of COVID‐19. Several waves of COVID‐19 have already occurred worldwide, and good‐quality vaccines and medicines should be available for ongoing as well as upcoming waves of the pandemic. Therefore, in silico studies have become an excellent tool for identifying possible ligands that could lead to the development of safer medicines or vaccines. Various phytoconstituents from plants and herbs with antiviral properties are studied further to obtain inhibitors of SARS‐CoV‐2. In silico screening of various molecular databases like PubChem, ZINC, Asinex Biol‐Design Library, and so on has been performed extensively for finding effective ligands against targets. Herein, in silico studies carried out by various researchers are summarized so that one can easily find the best molecule for further in vitro and in vivo studies.

In December 2019, a deadly viral infection started in the Wuhan province of China, where many people suffered from symptoms like pneumonia, flu, fever and headache. Because people from China travelled to other countries, this virus spread and became prevalent in almost 200 countries and territories within a short period of time and created havoc all over the world. Later, after considerable research, the root cause of this infection was found to be a virus that shows structural similarities to the SARS-related coronavirus. [1] [2] [3] On 20 January 2020, the National Health Commission of China confirmed the outbreak of a viral disease named Corona Virus Disease- that transmitted from human to human. [4, 5] The COVID-19-inducing virus is the seventh coronavirus that has been isolated from humans that causes severe infection. [6] Coronavirus that infects humans consists of a large family of viruses, that is, Alpha, Beta, Gamma and Delta coronaviruses. The COVID-19 strain of the coronavirus is a new member of the Beta-coronavirus that shows structural similarity to the SARS-related coronavirus and bat coronavirus. [7, 8] Under an electron microscope, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) appears as a positive single-stranded RNA virus with a crown-like appearance having a genome size of approximately 30,000 bp. [7, 9] SARS-CoV-2 possesses different types of glycoproteins, namely, spike glycoprotein (S), membrane protein (M), an envelope protein (E) and a nucleocapsid protein (N). [10, 11] The S protein of SARS-CoV-2 is important for the entry of the virus into the host cell, while M and E proteins are important for viral assembly, transport and release of viral particles. [10, [12] [13] [14] Inside the human body, SARS-CoV-2 uses transmembrane protease serine 2 (TMPRSS2), serine protease for S protein priming, and by using their S protein, it binds with the human receptor cells containing angiotensin-converting enzyme 2 (ACE2). [15] At the boundary between its two domains, the S protein cleaves into S1 and S2. The S2 subunit is important for the fusion mechanism, while S1 enables binding with the receptor ACE2 as it contains a receptor-binding domain (RBD). [16] After infection of cells by SARS-CoV-2, the RNA genome synthesizes two replicase polyproteins, that is, pp1a and pp1ab, which contain a replication/transcription complex, two proteases and several structural proteins. [17] In the case of other viruses such as HIV-1 and hepatitis C virus, the protease plays an important role in maturation of the viral protein in host cells, due to which targeting of this main protease is very important for the development of antiviral drugs. [18] Similarly, in SARS-CoV-2, the main protease (Mpro) plays a significant role in cleavage of polyproteins into individual functional pieces, which is responsible for replication and transcription of new viruses. It is a homo-dimeric protein that contains two protomers each and three domains, namely, Domain I, Domain II and Domain III, respectively. Among these, Domains I and II are made up of six antiparallel β-barrels that encompass residues 8-110 and 102-184, respectively, whereas Domain III is made up of a cluster of α-helices with residues from 201 to 303. Domain II is connected with Domain III with a long loop with residues from 185 to 200. There is a catalytic dyad Cys-His in the cleft between Domains I and II that is believed to have active proteolytic activity. [19, 20] For binding of any targeted drugs, there should be sufficient space in the binding or receptor site. In Mpro, the substrate-binding site is located in the cleft between Domains I and II. [21, 22] S1, S2, S3 and S4 are the subsites of the substrate-binding site as shown in Figure 1 . The amino acid substrates in Mpro are numbered -P4-P3-P2-P1 and P1ʹ-P2ʹ-P3ʹ from N terminus to C terminus, and the cleavage site is present between P1 and P1ʹ, with glutamic residues present in the P1 position.

Mpro performs a variety of important functions, such as maturing itself and other polyproteins, as well as cleaving two important F I G U R E 1 The crystal structure of the SARS-CoV-2 main protease (Mpro) is shown on the left, while a surface view of Mpro is shown on the right. Important domains and residues are shown in the crystal structure while four subsites of the substrate-binding cleft S1, S2, S3 and S4 are shown on the right. [20] SARS-CoV-2, severe acute respiratory syndrome coronavirus 2 polyproteins, pp1a and pp1ab, into 16 nonstructural proteins that are responsible for virus replication and maturation, as well as allowing viral particles to enter host cells. [20] Because of these important functions, Mpro is considered an effective target for anti-coronavirus drugs. [23] [24] [25] In spite of many research and experimental reports, few of the drug moieties are considered to be active against Mpro, but they are in the clinical trial stage, whereas Veklury (remdesivir) is the first US Food and Drug Administration (FDA)-approved antiviral drug for the treatment of COVID-19. Recently, Pfizer developed an antiviral oral tablet formulation called Paxlovid, where nirmatrelvir acts as an active pharmaceutical ingredient, and it was approved by the US FDA. Paxlovid works by inhibiting the 3C-like protease present in SARS-CoV-2. These new therapeutic agents will help in reducing mental, social, and economic stress and may improve quality of life. [26] However, the development of new drugs is very time consuming, and it should be cost-effective. Therefore, computer-aided drug design (CADD) can be used to test a large number of compounds in the lab and for screening of potent ligands or inhibitors that can target the majority of strains; this also helps to save cost, labour and time. [25, 27] 2 | TARGETING THE SARS-COV-2 MAIN PROTEASE MPRO A Michael acceptor inhibitor, which is also known as the N3 inhibitor, was designed and developed using an in silico method with the potential to inhibit SARS-CoV and MERS-CoV. [28] [29] [30] Regarding SARS-CoV-2, N3 can fit into the substrate-binding pocket of Mpro easily, which was identified by a molecular docking (MD) study, and N3 is quite effective against Mpro due to the capability of inhibiting Mpro in a time-dependent manner. [31] Mpro of SARS-CoV-2 is a homodimer enzyme consisting of three domains and having a substratebinding site with a catalytic dyad of His41 and Cys145 that is located between Domains I and II, whereas Domain III plays a role in dimerization between protomers as shown in Figure 2 . The inhibitors are designed to inhibit important catalytic function of this enzyme, which directly inhibits the virus from infecting further inside the host cells. [32] Havranek et al. carried out in silico studies to identify novel inhibitors as potential therapeutic targets against Mpro. Mpro is a 312 amino acid-containing protein that is mainly involved in viral replication. [24, 33] Since this protease is one of the potential targets for inhibition of COVID-19, [34] the X-ray crystal structure of this protease was used for docking purposes. Molecules 1-10 ( Figure 3 ) have been used for docking against the SARS-CoV-2 main protease, PDB ID: 6LU7. [24] After docking and molecular dynamics simulation (MDS) studies, the binding affinities for the PDB and MD structures were analysed. Among them (Figure 3) and −10.0 kcal/mol, respectively. This molecule has macrocyclic tissue factor-factor VIIa inhibitory activity, which can prevent blood coagulation after forming a complex with trypsin-like serine protease factor Xa. [35, 36] Du et al. reported that factor Xa is associated with the viral infectivity of SARS coronavirus by cleaving it into two functional units S1 and S2, which are further involved in enhancement of viral load. [37] Due to the presence of factor Xa in ACE2, the spike protein of SARS-CoV-2 can easily bind with ACE2 for viral entry. Therefore, macrocyclic tissue factor-factor VIIa inhibitor can be a useful target to inhibit SARS-CoV-2 replication because it inhibits factor Xa, which can further inhibit the entry of coronavirus into human cells. [24] Khan et al. carried out a comparative molecular study to investigate potential inhibitors against Mpro. They chose 23 drug molecules and (12) and saquinavir (13) with the best binding energies of −9.5, −9.1 and −9.5 kcal/mol, respectively. [38] Gaudencio and Pereira [26, 39] used a CADD that consisted of a ligand and a structure-based method to find out the lead molecule against SARS-CoV-2 main protease from a marine natural product (MNP). They used the QSAR model to screen the huge database CheMBL and successfully selected 20 molecules, which were further subjected to a MD study against Mpro (PDB ID: 6LU7) using AutoDock Vina (version 1.1). [40] Before the docking study, intrinsic ligand N3 and water molecules from 6LU7 were removed using AutoDock Tools.

After the docking study, it was found that 5 important natural marine products ( Figure 5 ) (4aR,6aR,12aS,12bS)-9-(3,4-dimethoxyphenyl)-4a,12a-dihydroxy-4,4,6a,12b-tetramethyl-4a,5,6,6a,12,12a-hexahydro- oxy}tetrahydro-2H-pyran-3,4,5-triol (16) , [4-(6- (17) and (6-bromo-1H- (18) showed the best lead-like properties with a good range of binding energies. Therefore, these molecules from marine origin can be further studied experimentally to identify a potential lead against the deadliest SARS-CoV-2 main protease. [39] In which was associated with viral entry into the human body. [41, 42] Primary screening from the natural compound library (containing around 100,000 compounds) was performed to select the top 5 best docked ligands. The ligands used in docking studies are natural compounds ( Figure 6 ), namely baicalin (19) , kaempferol (20) , limonin (21) , nimbolide (22) and quercetin (23) . The toxicities of ligand were checked using the ProTox-II toxicity study model. [43] All these ligands were docked using AutoDock 4.2 against three target proteins, which were downloaded from the RCSB Protein Data Bank Asp167, Ser798, Asp621, Tyr622, Lys801 and Lys624. [42] India has been a global hub for many herbal and medicinal plants. [44] Calendula officinalis is one such important medicinal plant, which is also known as marigold, that has various important phytochemicals and bioactive compounds, due to which it is widely used as an antiseptic, antiulcer, antibacterial, wound healing and antigenotoxic agent. [45] [46] [47] [53] Similarly, the diflavone compounds ( Figure 10 ), amentoflavone (36), bilobetin (38) and ginkgetin (39) , from the plant Torreya nucifera, and polyphenols from green tea such as epigallocatechin (40), (-)epicatechin gallate (41) and gallocatechin-3-gallate (42) were also found to act as Mpro inhibitors, with binding energies −9.2, −9.1, −9.0, −7.6, −8.2 and −9.0 kcal/mol, respectively. [54] Holanda et al.

carried out in silico studies on Mpro inhibitors from 1,2,3-triazolephthalimide derivatives, where the seven best compounds were subjected to a MD study; among them, one compound 2- (43) (45), carvacrol (46) and oleanolic acid (47) in silico study; they found that compound (3R,3aS,6aR)- (54) showed good binding energy and good stability tested by a MDS. [59] Choudhury investigated the active phytoconstituents of the Indian medicinal herb T. cordifolia (Giloy) against the Mpro protein, where ( Figure 11 ) berberine (55) showed better binding affinity with (−7.3 kcal/mol). [60] Rout et al. (62), showed potential Mpro-inhibiting property. [63] The ZINC database has become a useful tool for in silico studies. Kumar et al.

screened a large database of molecules and selected two molecules, (63) and ( (72) were found to act as potential Mpro inhibitors as compared to chloroquine and hydroxychloroquine sulphate. [67] Various ligands from the ZINC database were used for in silico studies to identify new hit molecules against the target protein. good binding affinity as well as good thermodynamic stability after binding with the target protein. [68] Andrographolides ( Figure 13 ) (74) obtained from Andrographis peninculata were subjected to various in silico studies such as target analysis, toxicity study and MD against Mpro, and showed good binding affinity, with a binding energy of −3.094 kcal/mol. [69] In silico studies on various phytochemicals can lead to the discovery of new Mpro inhibitors. Twelve important phytochemicals were subjected to various in silico studies, of which compounds ( Figure 13 ) glycyrrhizin (75), tryptanthrine (76) , rhein (77) and berberine (55) (Figure 11 ) showed significant binding affinity, with binding energies of −8.1, −8.2, −8.9 and −8.1 kcal/mol, respectively, and all these molecules also showed good drug-like properties. [70] From in silico studies of 20 compounds, four metabolites namely amentoflavone (36) (Figures 10 and 13) , guggulsterone (78), puerarin (79) and piperine (56) (Figure 11 ) showed strong binding affinity with Mpro of SARS-CoV-2, and further molecular dynamic studies confirmed their thermodynamic stability. [71] Prasanth et al. (113), showed the best binding affinity towards the target protein. [80] Majumder and Mandal screened the Sigma-Aldrich plant profiler chemical library by in silico docking against the main protease PDB ID: 6LU7 to identify Mpro inhibitors; of these ( Figure 15 ), compounds that showed the best binding energy are peonidin 3-O-glucoside was confirmed by performing a MDS study. [81] Ateeq Ahmed, in his study, screened more than 51 phytoconstituents of Juniperus procera

Hochst against Mpro, of which rutin (24) (Figure 7) showed the highest interaction score of −9.00 kcal/mol against the selected target. [ (124), with binding energy ranging from −12.37 to −9.58 kcal/mol. [84] Chatterjee et al. screened the top five hit compounds against SARS-CoV-2 Mpro and found that nafarelin (125) and icatibant (126) showed the best binding energies of −712.94 and −851.74 kJ/mol, respectively. [85] 3 | TARGETING THE SARS-COV-2 SPIKE PROTEIN (PDB ID: 6M0J)

It is known that the human ACE2 receptors are attacked by spike proteins of SARS-CoV-2. [86] [87] [88] The SARS-CoV-2 spike glycoproteins are homo-trimeric in nature, contain the S1 and S2 subunits in each of the spike monomers, which play a role in binding to cell receptors, lead to fusion between the viral membrane and host cell membrane, followed by successive entry of the virus, where cellular protease and serine protease TMPRSS2 promote cleavage of these two subunits.

Cryo-electron microscopy studies revealed that RBD carries out dissociation between the S1 subunit and ACE2, whereas the S2 subunit transforms from a metastable prefusion state to a more stable postfusion state, which is very much essential for membrane fusion. [89, 90] The RBD of SARS-CoV-2 with twisted pentameric β-sheets contains subunits β1, β2, β3, β4 and β7 with loops and connecting helices that form the main core. Figure 16 . [91] The potential drug target for the spike protein can be of three types such as host protease inhibition, fusion inhibition and neutralizing antibodies. Under host protease inhibition, TPC2, TMPRSS2 and cathepsin inhibitors can be used, under fusion inhibition, peptides that can target the HR1 domain can be one option and viracept can be used, which is an HIV-protease inhibitor, and finally, by using potential neutralizing antibodies, the binding tendency of the virus with various host cell targets such as RBD, S1, S2 and the N-terminus can be inhibited. [92] For an in silico model of identification of drugs, virtual screening and pharmacophore-based modelling play the most important roles. [93] Shehroz et al. used a CADD to identify the lead against spike protein of SARS-CoV-2. Screening of molecules with molecular weight <1.2 kDa was performed using the Cambridge Structural Database, the ZINC database, the Drug Bank and the TIMBAL database. [94] Molecules with protein-ligand interaction potential and those that followed the Lipinski rule were selected as leads against the desires pharmacophore. [95, 96] Out of 1327 hits, 10 compounds that showed the best fit scores above >50 were selected and docking was performed using AutoDock Vina against RBD of the S protein.

SARS-CoV-2 and all these eight compounds ( Figure 17 act as a competitive inhibitor against spike protein. [74] Propolis is a kind of supplement that is present in natural compounds and mostly used in Indonesia. [101] Various natural components of propolis were screened and docked against spike protein subunit S2, and it was found that four flavonoids, namely ( Figure (20), with promising binding affinity against the target protein; MD was performed to confirm their thermodynamic stability. [104] Wen et al. investigated and prepared a library of 8820 compounds after MD and found a single compound, trichostatin A (145), with significant Mpro inhibition activity. [105] 4 | TARGETING SARS-CoV-2 RNA-DEPENDENT RNA POLYMERASE (RdRp) RdRp, which is commonly known as nsp12, is involved in the mechanism of replication and transcription of SARS-CoV-2 viral proteins. [106] Polyproteins 1a and 1ab from open reading frames 1a (ORF1a) and

ORF1ab cleaved to form the RdRp core along with conjugation of core nsp7/nsp8. [107] The structure of the protein resembles a curled righthand grip divided into three subdomains, the finger domain (amino acid residues 398-581, 628-919), the palm domain (582-627, 688-815) and the thumb domain (816-919), as shown in Figure 19 . [41, 109] respectively. [112] 5 | TARGETING ACE2

ACE2 is a membrane protein receptor that is mainly expressed in the lungs, kidneys, heart and intestine. [113] It serves as a main portal for the entry of SARS-CoV-2 into the host cell; therefore, inhibition of ACE2 has become a potential novel target to minimize infections by preventing the entry of SARS-CoV-2. thermodynamic stability against target proteins. [115] Computational study revealed that flavonoids curcumin (163) and catechin (164) showed good binding affinity towards ACE2, with binding energies of −7.8 and −8.9 kcal/mol, respectively. [116] Horne and Vohl studied the effect of the polyphenolic compound resveratrol (165) and ACE2; after an in silico study it was found that the selected compounds showed good binding affinity with the target protein. [117] 6 | TARGETING MULTIPLE LIGANDS (174) showed the highest binding affinity. [120] Rameshwar et al. They found that lurasidone (194) and its derivatives that is lurasidone sulphoxide (195), lurasidone endo (196) and lurasidone exo (197) showed the best binding affinity against selected targets. Crytospirolepine, 10ʹ-hydroxyusambaresine, strychnopentamine, usararotenoid A and 12α-epi-milletosin showed good binding affinity towards inhibition of RdRp of SARS-CoV-2. Here, the best molecules that were found through in silico studies were compiled and they need to be studied further for effective drug development.

The financial support from the All India Council for Technical Education (AICTE), New Delhi, India is gratefully acknowledged (8-21/ FDC/RPS (NER)/POLICY-1/2020-21).

active site C, respectively

examined 19 hydrolysable tannins against 3CLpro of SARS-CoV-2, and they found that of these (Figure 25), pedunculagin (205), tercatain (206) and castalin (207) showed the best binding affinities of −18.58, −23.11 and −14.04 kcal/mol, respectively, on the selected target

Implication of in silico studies in the search for novel inhibitors against SARS-CoV-2

The authors declare no conflict of interest.

Udaya P. Singh https://orcid.org/0000-0003-0865-0502Hans R. Bhat https://orcid.org/0000-0002-9643-4916